Anhar Hassan1, Michael G Heckman2, J E Ahlskog3, Zbigniew K Wszolek4, Daniel J Serie2, Ryan J Uitti4, Jay A van Gerpen4, Michael S Okun5, Sruti Rayaprolu6, Owen A Ross7. 1. Department of Neurology, Mayo Clinic, Rochester, MN, USA. Electronic address: hassan.anhar@mayo.edu. 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA. 3. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 4. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. 5. Center for Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, USA. 6. Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA; Department of Neuroscience, University of Florida, Gainesville, FL, USA. 7. Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Abstract
INTRODUCTION: Dopamine and glutamate are crucial neurotransmitters in Parkinson disease (PD). While recent large meta-analyses reported that genetic variation of dopamine (DRD2, DRD3) and glutamine (NMDA, GRIN2B) neurotransmitter receptors was not associated with PD risk, they could conceivably influence PD phenotype. We studied the association of these receptor polymorphisms relating to PD age of onset. METHODS: There were 664 PD patients and 718 controls, all Caucasian, with stored DNA at Mayo Clinic, Jacksonville, Florida. Genotyping was performed for DRD2 (Taq 1A, rs1800497), DRD3 (rs6280), and NMDA (GRIN2B, rs7301328) polymorphisms with ABI Taqman assays. Single nucleotide polymorphism associations with age of onset were evaluated using dominant, recessive, and additive genotypic models. RESULTS: DRD3 variant carriers had an approximate 4.4-year decrease in mean age of onset when both copies of the minor allele were present (P = 0.0034) and an approximate 1.5-year decrease in mean age at onset for every additional minor allele (P = 0.023) (recessive and additive models, respectively). There was no association with age of onset for DRD2 or GRIN2B under any statistical model (all P ≥ 0.22). CONCLUSIONS: The DRD3 (rs6280) polymorphism, but not DRD2 (Taq1A) or GRIN2B, influences younger PD age of onset in the US Caucasian population. Validation of these findings in larger studies with other ethnic groups is indicated.
INTRODUCTION:Dopamine and glutamate are crucial neurotransmitters in Parkinson disease (PD). While recent large meta-analyses reported that genetic variation of dopamine (DRD2, DRD3) and glutamine (NMDA, GRIN2B) neurotransmitter receptors was not associated with PD risk, they could conceivably influence PD phenotype. We studied the association of these receptor polymorphisms relating to PDage of onset. METHODS: There were 664 PDpatients and 718 controls, all Caucasian, with stored DNA at Mayo Clinic, Jacksonville, Florida. Genotyping was performed for DRD2 (Taq 1A, rs1800497), DRD3 (rs6280), and NMDA (GRIN2B, rs7301328) polymorphisms with ABI Taqman assays. Single nucleotide polymorphism associations with age of onset were evaluated using dominant, recessive, and additive genotypic models. RESULTS:DRD3 variant carriers had an approximate 4.4-year decrease in mean age of onset when both copies of the minor allele were present (P = 0.0034) and an approximate 1.5-year decrease in mean age at onset for every additional minor allele (P = 0.023) (recessive and additive models, respectively). There was no association with age of onset for DRD2 or GRIN2B under any statistical model (all P ≥ 0.22). CONCLUSIONS: The DRD3 (rs6280) polymorphism, but not DRD2 (Taq1A) or GRIN2B, influences younger PDage of onset in the US Caucasian population. Validation of these findings in larger studies with other ethnic groups is indicated.
Authors: V Kaasinen; H Vilkman; J Hietala; K Någren; H Helenius; H Olsson; L Farde; J Rinne Journal: Neurobiol Aging Date: 2000 Sep-Oct Impact factor: 4.673
Authors: V McGuire; S K Van Den Eeden; C M Tanner; F Kamel; D M Umbach; K Marder; R Mayeux; B Ritz; G W Ross; H Petrovitch; B Topol; R A Popat; S Costello; A D Manthripragada; A Southwick; R M Myers; L M Nelson Journal: J Neurol Sci Date: 2011-06-12 Impact factor: 3.181
Authors: Mike A Nalls; Nathan Pankratz; Christina M Lill; Chuong B Do; Dena G Hernandez; Mohamad Saad; Anita L DeStefano; Eleanna Kara; Jose Bras; Manu Sharma; Claudia Schulte; Margaux F Keller; Sampath Arepalli; Christopher Letson; Connor Edsall; Hreinn Stefansson; Xinmin Liu; Hannah Pliner; Joseph H Lee; Rong Cheng; M Arfan Ikram; John P A Ioannidis; Georgios M Hadjigeorgiou; Joshua C Bis; Maria Martinez; Joel S Perlmutter; Alison Goate; Karen Marder; Brian Fiske; Margaret Sutherland; Georgia Xiromerisiou; Richard H Myers; Lorraine N Clark; Kari Stefansson; John A Hardy; Peter Heutink; Honglei Chen; Nicholas W Wood; Henry Houlden; Haydeh Payami; Alexis Brice; William K Scott; Thomas Gasser; Lars Bertram; Nicholas Eriksson; Tatiana Foroud; Andrew B Singleton Journal: Nat Genet Date: 2014-07-27 Impact factor: 38.330
Authors: Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu Journal: Ageing Res Rev Date: 2019-11-22 Impact factor: 10.895
Authors: Kenneth Blum; Rajendra D Badgaiyan; Georgia M Dunston; David Baron; Edward J Modestino; Thomas McLaughlin; Bruce Steinberg; Mark S Gold; Marjorie C Gondré-Lewis Journal: Mol Neurobiol Date: 2017-09-30 Impact factor: 5.590
Authors: Ahmad R Arshad; Siti A Sulaiman; Amalia A Saperi; Rahman Jamal; Norlinah Mohamed Ibrahim; Nor Azian Abdul Murad Journal: Front Mol Neurosci Date: 2017-10-31 Impact factor: 5.639